Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its generic Amoxicillin, supporting its strategy in generic antibiotics.

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its generic Amoxicillin, supporting its strategy in generic antibiotics. The product will be offered in multiple dosage forms and strengths and is anticipated to ship to Canadian pharmacies in August 2026.

Amoxicillin global sales were estimated at $4.9–$5.9 billion in 2025, with 2.9% CAGR projected to about $6.4 by 2031. Canada represents roughly 2% of global Amoxicillin sales.

Positive

• Canadian regulatory approval enables launch of generic Amoxicillin in new market
• Planned product availability in August 2026 offers near-term commercialization timeline
• Amoxicillin market estimated at $4.9–$5.9 billion in 2025
• Projected 2.9% CAGR for global Amoxicillin market through 2031
• Canada estimated to represent about 2% of global Amoxicillin sales

Negative

• None.

Argus May 21 session

+40.59% close to close Open Argus

Details

News Market Reaction – SBFM

In the May 21 session, SBFM gained 40.59%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +40.6% in the session following this news. A strong positive reaction aligns with S...

Analysis

The stock surged +40.6% in the session following this news. A strong positive reaction aligns with Sunshine Biopharma’s strategy of expanding its Canadian generic portfolio. Prior earnings showed revenue growth to $36.31 million, while recent financings raised about $6.0 million to support operations. The Amoxicillin approval targets a global market estimated up to $5.9 billion, with Canada at about 2%. Investors would still need to monitor dilution risk from past offerings and execution on the August 2026 launch.

Key Figures

Global Amoxicillin sales 2025 (low end): $4.9 billion Global Amoxicillin sales 2025 (high end): $5.9 billion Amoxicillin CAGR: 2.9% +5 more

Global Amoxicillin sales 2025 (low end)

$4.9 billion

Estimated 2025 global Amoxicillin sales revenue

Global Amoxicillin sales 2025 (high end)

$5.9 billion

Estimated 2025 global Amoxicillin sales revenue

Amoxicillin CAGR

2.9%

Estimated compounded annual growth rate through 2031

Projected market size 2031

$6.4 USD

Projected Amoxicillin market size by 2031

Canada share of market

2%

Canadian share of global Amoxicillin market

Launch timing

August 2026

Expected shipping of Sunshine’s Amoxicillin to Canadian pharmacies

Price move

-16.52%

SBFM 24-hour price change before this news

52-week range

$0.2812–$2.43

52-week low and high before this news

Historical Context

3 past events · Latest: May 19

3 events

1. May 19

   Equity offering close

   24h Move

   -8.2%

   Closed public offering raising ~$6.0M via units and Series C warrants.

2. May 18

   Equity offering pricing

   24h Move

   +79.5%

   Priced $6.0M best-efforts public offering with common and pre-funded units.

3. Apr 06

   Annual earnings report

   24h Move

   +11.5%

   Reported $36.31M revenue (+4.1% YoY) with higher gross profit but wider net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

amoxicillin, penicillin-class antibiotic, urinary tract infections, cagr

4 terms

amoxicillin medical

"approval of its generic Amoxicillin formulation for the Canadian market."

Amoxicillin is a widely used antibiotic medicine that kills or stops the growth of bacteria to treat infections such as ear, throat, sinus and urinary tract infections. Think of it as a targeted cleaner that helps remove unwanted bacterial invaders; its popularity, patent status, supply levels and regulatory approvals matter to investors because they directly affect drug sales, profit margins and the competitive landscape for companies in the pharmaceutical and healthcare sectors.

penicillin-class antibiotic medical

"Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat"

A penicillin-class antibiotic is a medicine derived from the original penicillin family that kills or stops bacteria by weakening their protective outer layers, and is commonly used to treat a wide range of infections. Investors care because these drugs behave like a company's dependable workhorse product: their clinical effectiveness, patent protection, regulatory approvals, manufacturing capacity and the rise of bacterial resistance directly affect sales, margins and future demand.

urinary tract infections medical

"pneumonia, bronchitis, urinary tract infections, skin and soft‑tissue infections"

Urinary tract infections are bacterial infections of the body’s plumbing that includes the bladder, urethra and sometimes the kidneys, causing symptoms like painful urination, urgency and fever when more serious. They matter to investors because they are common, drive steady demand for treatments, diagnostics and prevention products, and can influence healthcare costs, regulatory attention and revenue prospects for companies developing drugs, tests or medical devices related to diagnosis and treatment.

cagr financial

"expected to increase at a compounded annual growth rate (CAGR) of 2.9%"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Amoxicillin formulation for the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.

Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft‑tissue infections, and dental infections. Sunshine Biopharma's generic version will be available in multiple dosage forms and strengths, ensuring broad accessibility for prescribers and pharmacists. It is anticipated that Sunshine Biopharma's Amoxicillin will be ready to ship to pharmacies in August 2026.

Amoxicillin global sales revenue in 2025 was estimated to be between $4.9 billion and $5.9 billion USD and is expected to increase at a compounded annual growth rate (CAGR) of 2.9% reaching approximately $6.4 USD by 2031. The major drivers for this market growth include the increasing prevalence of bacterial infections worldwide, the rising demand for affordable antibiotic treatments, and the growing adoption Amoxicillin in pediatric and adult care. The Canadian market comprises approximately 2% of the global total (IQVIA, OECD, Health Canada).

"We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sunshine Biopharma (SBFM) announce about Canadian approval for generic Amoxicillin?

Sunshine Biopharma announced Canadian regulatory approval for its generic Amoxicillin formulation. According to Sunshine Biopharma, this approval allows the company to enter the Canadian antibiotic market with multiple dosage forms and strengths, expanding its generic portfolio and supporting access to affordable treatments.

When will Sunshine Biopharma’s generic Amoxicillin be available in Canadian pharmacies?

Sunshine Biopharma expects its generic Amoxicillin to be ready to ship in August 2026. According to Sunshine Biopharma, the product will be supplied in multiple dosage forms and strengths, enabling broad accessibility for prescribers, pharmacists, and patients across Canada.

How large is the global Amoxicillin market mentioned in the Sunshine Biopharma (SBFM) announcement?

The global Amoxicillin market was estimated at $4.9–$5.9 billion in 2025. According to Sunshine Biopharma, the market is projected to grow at a 2.9% compounded annual rate, reaching approximately $6.4 by 2031, with Canada representing about 2% of global sales.

What percentage of global Amoxicillin sales does Canada represent in Sunshine Biopharma’s outlook?

Canada is estimated to represent about 2% of global Amoxicillin sales. According to Sunshine Biopharma, this share is based on data from IQVIA, OECD, and Health Canada, highlighting a defined but meaningful national market for its newly approved generic product.

How does the Canadian Amoxicillin approval support Sunshine Biopharma’s generic antibiotics strategy?

The approval adds Amoxicillin to Sunshine Biopharma’s expanding generic antibiotics portfolio. According to Sunshine Biopharma, the launch aligns with its mission to deliver essential, high-quality medications at competitive prices while maintaining strong quality and compliance standards in key markets like Canada.

What medical uses of Amoxicillin are highlighted in Sunshine Biopharma’s Canadian approval news?

Amoxicillin is described as a widely prescribed penicillin-class antibiotic for many bacterial infections. According to Sunshine Biopharma, indicated uses include ear, sinus, throat, respiratory, urinary tract, skin, soft-tissue, and dental infections in both pediatric and adult patients.